GlobeNewswire·Jul 27, 2026, 4:01 PM ET

Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer

Kymera Therapeutics appointed Terence Rooney, MD, as Chief Medical Officer to lead clinical development strategy for its oral immunology portfolio.
Dr. Rooney succeeds Jared Gollob, MD, who will retire after eight years of leadership and will serve as an advisor through the end of 2026.
Dr. Rooney previously served as Senior Vice President, Portfolio and Asset Management Leader, Immunology, at Johnson & Johnson.
His prior career includes senior roles at Eli Lilly and Roche, with experience spanning small molecules, biologics, cell therapies, and therapeutic areas like dermatology, rheumatology, and gastroenterology.
Dr. Rooney contributed to the marketing of medicines including ICOTYDE, IMAAVY, OLUMIANT, STELARA, and TREMFYA.
He holds medical degrees from the Royal College of Surgeons in Ireland, completed training at Dublin Academic Teaching Hospitals and the University of California, San Francisco, and holds a doctorate from the National University of Ireland.
Nello Mainolfi, PhD, Founder, President, and CEO of Kymera, cited Dr. Rooney's experience as crucial for advancing the company's pipeline of targeted protein degradation medicines.
Kymera is a clinical-stage biopharmaceutical company founded in 2016 that focuses on oral small molecule degraders for immunological diseases.